Switzerland Latest Market For Viagra
Pfizer's new oral drug for male erectile dysfunction, Viagra(sildenafil), has been approved and launched in Switzerland. The product has been available in some Swiss cantons - notably Geneva and Tessin - for some weeks, according to AFX News. The drug was first launched in the USA.
Viagra was recently recommended for approval by the European Commission's Committee on Proprietary Medicinal Products (Marketletter June 8), and other approvals and introductions in Europe are expected in the near future.
The Swiss regulatory authority has said that it took into account the reports of deaths in people taking the drug in the USA, and that it would be maintaining a scrupulous watch over the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze